Association of SGLT2 Inhibitor Use With Outcomes in Patients With Frailty Hospitalized for Acute Heart Failure: Insights From a Multicenter Japanese Registry
Journal of the American Heart Association · 04.08.2026 · 15 (15)
DOI: 10.1161/jaha.125.048748 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 04.08.2026. Verfasst von Ayami Naito und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology National Defense Medical College Tokorozawa Saitama Japan. Hauptthemen laut MEDLINE: Frailty, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Herzinsuffizienz, Gerontologische Pflege
Abstract (Originalsprache)
Background
SGLT2 (sodium–glucose cotransporter‐2) inhibitors (SGLT2is) improve outcomes in heart failure (HF), but evidence in patients with frailty and acute HF (AHF) is limited. This study investigated the association between SGLT2i use at discharge and outcomes in patients with AHF, with a focus on frailty.
Methods
We analyzed 5579 patients hospitalized for AHF enrolled between 2018 and 2024 in the prospective WET‐HF2 (West Tokyo Heart Failure 2) registry in Japan (age 79 years, 43% women, body mass index 23.1, 23% ischemic cause, left ventricular ejection fraction 45%, 24% SGLT2is at discharge). Frailty was assessed using the Clinical Frailty Scale (≥4; 63%), and complementary analyses were performed using frailty‐related factors (low body mass index, reduced activities of daily living, malnutrition, and dementia). The primary outcome was a composite of cardiac death or HF rehospitalization within 1 year, which occurred in 766 patients (18%). A propensity score was calculated using variables associated with SGLT2i prescription.
Results
After propensity score–based inverse probability of treatment weighting adjustment, SGLT2i use was associated with a lower risk of the primary outcome (hazard ratio [HR], 0.76, P =0.045). This association was more pronounced in patients with frailty (HR, 0.59, P =0.005), but not in patients without frailty (HR, 1.18; P interaction =0.010). Analyses using frailty‐related factors yielded similar patterns. At 1 year, SGLT2i use at discharge was not associated with deterioration in body mass index or nutritional status.
Conclusions
In this observational registry, SGLT2i use at discharge was associated with improved outcomes in patients with AHF, particularly those with frailty, without evidence of nutritional harm. These findings support the potential safety of SGLT2is in patients with frailty and AHF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology National Defense Medical College Tokorozawa Saitama Japan.
- Department of Cardiology Kyorin University Hospital Tokyo Japan.
- Department of Cardiology Saitama Medical University International Medical Center Hidaka Saitama Japan.
- Department of Cardiology Tokyo Saiseikai Central Hospital Tokyo Japan.
- Department of Cardiology, National Hospital Organization Tokyo Medical Center Tokyo Japan.
- Department of Cardiology Showa Medical University Tokyo Japan.
ORCID-Profile: Ayami Naito, Yuji Nagatomo, Akane Kawai, Ayumi Goda, Takashi Kohno, Shintaro Nakano, Kazutaka Miyamoto, Munehisa Sakamoto, Satoshi Higuchi, Mitsunobu Kitamura, Yasuyuki Shiraishi, Satoshi Shoji, Shun Kohsaka, Takeshi Adachi
Zitieren
APA
Naito, A., Nagatomo, Y., Kawai, A., Ikegami, Y., Goda, A., Kohno, T., Nomoto, M., Nakano, S., Miyamoto, K., Sakamoto, M., Higuchi, S., Kitamura, M., Shiraishi, Y., Shoji, S., Kohsaka, S., Adachi, T., & Yoshikawa, T. (2026). Association of SGLT2 Inhibitor Use With Outcomes in Patients With Frailty Hospitalized for Acute Heart Failure: Insights From a Multicenter Japanese Registry. Journal of the American Heart Association, 15(15). https://doi.org/10.1161/jaha.125.048748
Vancouver
Naito A, Nagatomo Y, Kawai A, Ikegami Y, Goda A, Kohno T, et al. Association of SGLT2 Inhibitor Use With Outcomes in Patients With Frailty Hospitalized for Acute Heart Failure: Insights From a Multicenter Japanese Registry. Journal of the American Heart Association. 2026;15(15). doi:10.1161/jaha.125.048748
BibTeX
@article{Naito2026,
author = {Naito, Ayami and Nagatomo, Yuji and Kawai, Akane and Ikegami, Yukinori and Goda, Ayumi and Kohno, Takashi and Nomoto, Michiru and Nakano, Shintaro and Miyamoto, Kazutaka and Sakamoto, Munehisa and Higuchi, Satoshi and Kitamura, Mitsunobu and Shiraishi, Yasuyuki and Shoji, Satoshi and Kohsaka, Shun and Adachi, Takeshi and Yoshikawa, Tsutomu},
title = {Association of SGLT2 Inhibitor Use With Outcomes in Patients With Frailty Hospitalized for Acute Heart Failure: Insights From a Multicenter Japanese Registry},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {15},
doi = {10.1161/jaha.125.048748}
}
EUVIMED